2Assoc. Prof., Ümraniye Training and Research Hospital, Eye Clinic, Istanbul, Türkiye DOI : 10.37845/ret.vit.2023.32.39 Purpose: To compare the functional and anatomical efficacy of intravitreal injection of Ranibizumab and Aflibercept in the treatment of diabetic macular edema.
Material and Method: The medical records of patients who received intravitreal ranibizumab or aflibercept injection due to diabetic macular edema (DME) in our clinic were reviewed retrospectively. We included patients who received intravitreal ranibizumab injections in Group 1 and patients who received intravitreal aflibercept injections in Group 2. Best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressures (IOP), and the total number of injections at baseline, 1st, 3rd, 6th, and 12th-month controls were compared between the two groups.
Results: We included 31 eyes in Group-1 and 35 eyes in Group-2. The baseline mean BCVA in Group-1 was 0.64±0.34 logMAR and increased significantly to 0.37±0.25 logMAR in the 12th month. The baseline mean BCVA in Group-2 was 0.69±0.34 logMAR and increased significantly to 0.35±0.18 logMAR at the 12th month. The baseline mean CMT in Group-1 was 432.13±114.55 ?m and increased significantly to 291.23±62.21 ?m at 12th month. The baseline mean CMT in Group-2 was 458.46±90.43 ?m and increased significantly to 298.26±43.8 ?m at 12th month. There was no significant difference between the increase in BCVA and the decrease in CMT between the two groups (p>0.05). The mean number of injections for 12 months was 7.2 (6-9) in Group-1, and 6.9 (68) in Group-2, and there was no statistically significant difference between the groups. (p> 0.05).
Conclusion: The efficacy of both drugs in the treatment of diabetic macular edema is similar.
Keywords : Aflibercept, Diabetic macular edema, Ranibizumab